EyePoint Pharmaceuticals Set for Key Investor Conferences

EyePoint Pharmaceuticals to Participate in Major Investor Conferences

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), dedicated to advancing treatments for patients with serious retinal diseases, is gearing up for participation in several significant investor conferences. This engagement highlights the company's commitment to transparency and investor engagement.

Upcoming Conference Details

The management of EyePoint is excited to announce participation in multiple forums designed to connect with potential investors and stakeholders.

• Citi’s 2025 BioPharma Back to School Conference
  Format: Fireside Chat
  Scheduled for: Tuesday, September 2, 2025 at 2:30 p.m. ET
• Cantor Global Healthcare Conference
  Format: Fireside Chat
  Scheduled for: Wednesday, September 3, 2025 at 2:45 p.m. ET
• Morgan Stanley 23rd Annual Global Healthcare Conference
  Format: 1x1 Investor Meetings
  Scheduled for: Tuesday, September 9, 2025

Interested parties will have the opportunity to access a live webcast of these presentations along with recorded replays available in the Investors section of the company's website.

Understanding EyePoint Pharmaceuticals

As a clinical-stage biopharmaceutical company, EyePoint Pharmaceuticals aims to develop and commercialize innovative therapeutics that significantly improve patient outcomes for those suffering from retinal diseases. One of their standout candidates, DURAVYU™, represents a groundbreaking approach to delivering treatment for retinal illnesses exacerbated by excessive VEGF levels.

This pioneering investigational treatment utilizes a patent-protected technology, enhancing its delivery and effectiveness in managing conditions related to age-related macular degeneration (AMD) and diabetic macular edema (DME). Currently, DURAVYU is undergoing pivotal Phase 3 trials for wet AMD, with preliminary results expected in the near future. The progress in these trials reaffirms EyePoint's dedication to addressing the unmet needs of patients.

Committed to Innovation and Community

EyePoint’s commitment extends beyond just treatment development; it focuses on partnership with the retina community to drive advancement in patient care. Over the past three decades, the company has achieved tremendous success, illustrated by four approved drugs and countless patients having benefitted from their innovative solutions.

Headquartered in Watertown, Massachusetts, and with a commercial manufacturing facility located in Northbridge, EyePoint continues to build on its strong foundation of research and development aimed at ocular health.

Moreover, vorolanib, an active component in DURAVYU, strikes a significant chord in their innovative framework, having a dedicated licensing agreement with Equinox Sciences to manage its potential across various ophthalmic therapies outside of certain Asian markets.

While DURAVYU has made promising advancements, it remains an investigational product, awaiting regulatory approval from the FDA. Its proprietary name has been conditionally accepted, but there is still uncertainty regarding the full approval timeline.

Investor Relations and Contacts

For those seeking to connect with the company or gain further insights into EyePoint's ongoing developments, the Investor Relations team is readily accessible. Tanner Kaufman and Jenni Lu represent the team, welcoming inquiries via direct lines for personalized assistance.

EyePoint values open communication with shareholders and prospective investors, striving to keep all stakeholders informed about their progress and innovations in the biopharmaceutical landscape for retinal diseases.

Frequently Asked Questions

What is EyePoint Pharmaceuticals' main focus?

EyePoint Pharmaceuticals specializes in developing innovative therapeutics for serious retinal diseases.

What product is EyePoint currently focusing on?

The company is concentrating on DURAVYU™, an investigational treatment for retinal diseases.

When are the upcoming investor conferences?

EyePoint will participate in conferences on September 2, 3, and 9 in 2025.

How can one access the conference presentations?

Presentations can be accessed via a live webcast on the Investors section of EyePoint’s website.

What is EyePoint's commitment to the community?

EyePoint aims to partner with the retina community to enhance patient lives through innovative therapies.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.